Cardiac Biomarkers Testing Market 2024 - By Size, Segmentation, Application, Outlook And Opportunities Analysis By 2033


Posted January 29, 2024 by saitbrc

Global cardiac biomarkers testing market size is expected to reach $21.31 Bn by 2028 at a rate of 11.8%, segmented as by biomarkers type, creatine kinase (ck-mb), troponins, myoglobin, natriuretic peptides (bnp and nt-probnp)
 
The Cardiac Biomarkers Testing by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cardiac Biomarkers Testing Market:
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

According to The Business Research Company’s Cardiac Biomarkers Testing, The cardiac biomarkers testing market size has grown rapidly in recent years. It will grow from $12.15 billion in 2023 to $13.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, aging population, awareness and education initiatives, government initiatives and healthcare policies, increasing healthcare expenditure.

The cardiac biomarkers testing market size is expected to see rapid growth in the next few years. It will grow to $21.31 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to personalized medicine, rising global burden of cardiovascular diseases, integration of artificial intelligence (ai) in diagnostics, expansion of point-of-care testing, increasing emphasis on early disease detection. Major trends in the forecast period include technological advancements, advancements in ai-assisted diagnostics, point-of-care testing (poct) growth, multiplexing capabilities, biomarker discovery and validation.

The increasing prevalence of cardiovascular diseases is expected to boost the growth of the cardiac biomarkers testing market going forward. Cardiovascular disease refers to a type of condition that affects the heart or blood vessels. Cardiac biomarker tests assist in determining the levels of biomarkers to immediately determine the severity of a heart attack and its magnitude. Hence, an increase in the prevalence of cardiovascular diseases will lead to an increase in the demand for cardiac biomarker testing solutions. For instance, in August 2022, according to the American College of Cardiology, a US-based professional medical organization, the expected rates of cardiovascular risk factors and disease will considerably rise in the United States by the year 2060. Therefore, an increase in the prevalence of cardiovascular diseases is driving the growth of the cardiac biomarkers testing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

The cardiac biomarkers testing market covered in this report is segmented –
1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified albumin (IMA), Other Biomarkers Types
2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications
3) By End-User: Hospitals, Specialty Clinics

Top Major Players
Abbott Laboratories
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Siemens Healthineers AG

Product innovations are a key trend gaining popularity in the cardiac biomarker testing market. Major companies operating in the cardiac biomarker testing market are focusing on developing innovative products to sustain their market position. For instance, in October 2021, Siemens Healthcare GmbH, a Germany-based medical technology company, launched the Atellica VTLi Patient-Side Immunoassay Analyzer. The unique feature of the Atellica VTLi Patient-Side Immunoassay Analyzer is its high-sensitivity troponin I test from a fingerstick sample. Clinicians and healthcare professionals can enhance outcomes for patients by using it to help diagnose a heart attack fast and reliably in eight minutes.

The cardiac biomarkers testing market report table of contents includes:
1. Executive Summary
2. Cardiac Biomarkers Testing Market Characteristics
3. Cardiac Biomarkers Testing Market Trends And Strategies
4. Cardiac Biomarkers Testing Market - Macro Economic Scenario
5. Global Cardiac Biomarkers Testing Market Size and Growth
...............................
31. Global Cardiac Biomarkers Testing Market Competitive Benchmarking
32. Global Cardiac Biomarkers Testing Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Cardiac Biomarkers Testing Market
34. Cardiac Biomarkers Testing Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By TBRC
Country United States
Categories Medical
Tags cardiac biomarkers testing market , cardiac biomarkers testing market share , cardiac biomarkers testing market size
Last Updated January 29, 2024